利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

76 条记录 (耗时 0.012 秒)

    PROCESS FOR PREPARING ORAL CALCIUM COMPOSITIONS
    1.
    发明授权
    PROCESS FOR PREPARING ORAL CALCIUM COMPOSITIONS 有权
    VERFAHREN ZUR HERSTELLUNG VON ORALEN CALCIUM ZUSAMMENSETZUNGEN

    公开(公告)号：EP1128815B1

    公开(公告)日：2006-10-18

    申请号：EP99952710.4

    申请日：1999-11-05

    申请人： Nycomed Pharma AS

    发明人： PIENE, Jan Yngvar ,  SCHMIDT, Dina Dogger

    IPC分类号： A61K9/16

    CPC分类号： A61K9/0007 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2077 ,  Y10S514/819

    摘要： The invention provides a process for the preparation of an orally administrable calcium composition, said process comprising the steps of: (i) obtaining a physiologically tolerable particulate calcium compound having a mean particle size in the range 3 to 40 mu m, having a crystalline structure and having a surface area of 0.1 to 1.2 m /g; (ii) mixing said calcium compound with a water-soluble diluent and an aqueous solution of a water soluble binder in a fluid bed granulation apparatus and drying the resulting mixture to produce a first granulate; (iii) optionally mixing said first granulate with one or more further components to produce a second granulate; and (iv) optionally compressing said first or second granulate to form tablets.

    摘要翻译： 本发明提供了一种制备可口服给药的钙组合物的方法，所述方法包括以下步骤：（i）获得平均粒度在3至40μm范围内的生理学上可耐受的颗粒状钙化合物，具有结晶结构并具有 表面积为0.1〜1.2m 2 / g; （ii）将所述钙化合物与水溶性稀释剂和水溶性粘合剂的水溶液混合在流化床造粒装置中并干燥所得混合物以产生第一颗粒; （iii）任选地将所述第一颗粒与一种或多种其它组分混合以产生第二颗粒; 和（iv）任选地压缩所述第一或第二颗粒以形成片剂。

    MAGENSÄURE BINDENDE, PHARMAZEUTISCHE ZUBEREITUNG
    5.
    发明授权
    MAGENSÄURE BINDENDE, PHARMAZEUTISCHE ZUBEREITUNG 失效
    胃酸结合药物制剂。

    公开(公告)号：EP0490920B1

    公开(公告)日：1993-12-08

    申请号：EP90912814.2

    申请日：1990-09-06

    申请人： Gergely, Gerhard, Dr.

    发明人： GERGELY, Gerhard ,  GERGELY, Thomas ,  GERGELY, Irmgard

    IPC分类号： A61K31/29 ,  A61K33/24 ,  A61K9/16 ,  A61K9/46 ,  A61K33/08 ,  A61K33/12 ,  A23L2/40

    CPC分类号： A61K31/29 ,  A61K9/0007 ,  A61K33/245 ,  Y10S514/819

    摘要： A granulate, possibly pressed into the form of tablets, contains at least one insoluble, complex bound or barely soluble material in powder form, which can bind or neutralize acids, and which does not react with the acid of the effervescent system, and an effervescent system, consisting of at least one organic, edible acid and at least one alkaline or alkaline earth carbonate and/or bicarbonate. The active material is present in a quantity of 5 to 50 %, preferably 8 to 30 %, and in particular 12 to 25 % by weight. It has an acid binding power of between 2 and 40, preferably 3.5 to 25 mEq/g, does not react with the acid of the effervescent system and raises the pH value in 0.1 n HCl during 2 min. by a maximum of 0.5. It consists in particular of magnesium trisilicate, sucralfate and/or a bismuth salt. Each granule contains at least one acid component, at least one carbonate component and at least one active material bound to one another. The binding of the granulate components together is effected by a reaction product from an acid with a carbonate component and/or by at least one hydrocolloid, in particular xanthane, maltodextrin, galactomanane and/or tragacanth.

    Phenethanolamine derivatives
    9.
    发明公开
    Phenethanolamine derivatives 失效
    苯酚胺衍生物

    公开(公告)号：EP0317206A3

    公开(公告)日：1990-02-07

    申请号：EP88310661.9

    申请日：1988-11-11

    申请人： GLAXO GROUP LIMITED

    发明人： Mitchell William Leonard ,  Skidmore Ian Frederick ,  Lunts Lawrence Henry Charles ,  Finch Harry ,  Naylor Alan ,  Hartley David

    IPC分类号： C07C215/20 ,  C07C323/10 ,  A61K31/135 ,  A61K31/18

    CPC分类号： C07C65/11 ,  Y10S514/819 ,  Y10S514/826 ,  Y10S514/886 ,  Y10S514/887 ,  Y10S514/913 ,  Y10S514/925 ,  Y10S514/927

    摘要： The invention provides compounds of the general formula (I)
    and physiologically acceptable salts and solvates thereof, wherein
    Ar represents the group
    where Q¹ represents a straight or branched C₁₋₃alkylene group,
    where Q² represents a group R³CO-, R³NHCO-, R³R⁴NSO₂- or R⁵SO₂-, where R³ and R⁴ each represent a hydrogen atom or a C₁₋₃alkyl group, and R⁵ represents a C₁₋₃alkyl group,
    R represents a hydrogen atom or a C₁₋₃alkyl group;
    R¹ and R² each independently represent a hydrogen atom or a methyl or ethyl group; and
    k represents an integer from 1 to 8;
    m represents zero or an integer from 2 to 7, and;
    n represents an integer from 1 to 7 with the proviso that the sum total of k, m and n is 4 to 12;
    X represents an oxygen or sulphur atom, and;
    Y and Z each represent a bond, or an oxygen or sulphur atom with the proviso that when Y is a bond m is zero, or when Y represents an oxygen or sulphur atom m is an integer from 2 to 7, or when Y and Z each independently represent an oxygen or sulphur atom then n is an integer from 2 to 7;
    Q represents a naphthalenyl group which may optionally be substituted by one or two groups selected from C₁₋₄alkyl, C₁₋₄alkoxy, hydroxy and halogen. The compounds have a stimulant action at β₂-­adrenoreceptors and may be used in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.